Evidence map›Paper›PMID 23503467›Full record

ArticleOncogene2014

A novel splice variant of calcium and integrin-binding protein 1 mediates protein kinase D2-stimulated tumour growth by regulating angiogenesis.

M Armacki, G Joodi, S C Nimmagadda, L de Kimpe, G V Pusapati, S Vandoninck, J Van Lint, A Illing, T Seufferlein

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Cytosolic interaction of type III human CD38 with CIB1 modulates cellular cyclic ADP-ribose levels.Proceedings of the National Academy of Sciences of the United States of America · 2017
    Article
  9. Article
  10. CIB1: a small protein with big ambitions.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2016
    Review
  11. Article
  12. Protein kinase D2 silencing reduced motility of doxorubicin-resistant MCF7 cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015
    Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

M Armacki1] Department of Internal Medicine I, University of Ulm, Ulm, Baden-Wuerttemberg, Germany [2] Department of Internal Medicine I, Martin-Luther-University Halle-Wittenberg, Halle(Saale), Germany.
G JoodiDepartment of Internal Medicine I, Martin-Luther-University Halle-Wittenberg, Halle(Saale), Germany.
S C NimmagaddaDepartment of Internal Medicine I, Martin-Luther-University Halle-Wittenberg, Halle(Saale), Germany.
L de Kimpe1] Academic Medical Center (AMC), University of Amsterdam, Amsterdam, The Netherlands [2] Department of Cellular and Molecular Medicine, Faculty of Medicine, KU Leuven, Belgium.
G V PusapatiDepartment of Biochemistry, Stanford University School of Medicine, Stanford, CA, USA.
S VandoninckDepartment of Cellular and Molecular Medicine, Faculty of Medicine, KU Leuven, Belgium.
J Van LintDepartment of Cellular and Molecular Medicine, Faculty of Medicine, KU Leuven, Belgium.
A IllingDepartment of Internal Medicine I, University of Ulm, Ulm, Baden-Wuerttemberg, Germany.
T Seufferlein1] Department of Internal Medicine I, University of Ulm, Ulm, Baden-Wuerttemberg, Germany [2] Department of Internal Medicine I, Martin-Luther-University Halle-Wittenberg, Halle(Saale), Germany.
KU Leuven · BEMartin Luther University Halle-Wittenberg · DEStanford University · USUniversität Ulm · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Protein kinase D2 (PKD2) is a member of the PKD family of serine/threonine kinases, a subfamily of the CAMK super-family. PKDs have a critical role in cell motility, migration and invasion of cancer cells. Expression of PKD isoforms is deregulated in various tumours and PKDs, in particular PKD2, have been implicated in the regulation of tumour angiogenesis. In order to further elucidate the role of PKD2 in tumours, we investigated the signalling context of this kinase by performing an extensive substrate screen by in vitro expression cloning (IVEC). We identified a novel splice variant of calcium and integrin-binding protein 1, termed CIB1a, as a potential substrate of PKD2. CIB1 is a widely expressed protein that has been implicated in angiogenesis, cell migration and proliferation, all important hallmarks of cancer, and CIB1a was found to be highly expressed in various cancer cell lines. We identify Ser(118) as the major PKD2 phosphorylation site in CIB1a and show that PKD2 interacts with CIB1a via its alanine and proline-rich domain. Furthermore, we confirm that CIB1a is indeed a substrate of PKD2 also in intact cells using a phosphorylation-specific antibody against CIB1a-Ser(118). Functional analysis of PKD2-mediated CIB1a phosphorylation revealed that on phosphorylation, CIB1a mediates tumour cell invasion, tumour growth and angiogenesis by mediating PKD-induced vascular endothelial growth factor secretion by the tumour cells. Thus, CIB1a is a novel mediator of PKD2-driven carcinogenesis and a potentially interesting therapeutic target.

Indexed as

Calcium-Binding ProteinsCell Line, TumorCell MovementChorioallantoic MembraneHeLa CellsHumansNeovascularization, PathologicPhosphorylationRNA SplicingTRPP Cation ChannelsVascular Endothelial Growth Factor ACalcium-Binding ProteinsCIB1 protein, humanTRPP Cation ChannelsVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID23503467
OpenAlexW2083953028

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.